AIM
CYTK icon

Alambic Investment Management’s Cytokinetics CYTK Stock Holding History

Alambic Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,949
Closed -$205K – 509
2017
Q2 		$205K Sell
16,949
-11,551
-41% -$161K 0.02% 508
2017
Q1 		$366K Buy
28,500
+15,300
+116% +$179K 0.05% 466
2016
Q4 		$160K Buy
+13,200
New +$140K 0.03% 517

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Alambic Investment Management's CYTK Position: Q3 2017 in Review

Alambic Investment Management sold out of Cytokinetics (CYTK) in Q3 2017, closing a stake of 16,949 shares — an estimated $205K sold.

Alambic Investment Management first reported a position in CYTK in Q4 2016 and held it in 3 quarters. The position peaked at $366K in Q1 2017. 132 funds tracked by Wall St. Rank hold CYTK as of Q3 2017.

  • Alambic Investment Management reported no remaining Cytokinetics position as of Q3 2017 after selling out during the quarter.
  • Alambic Investment Management sold 16,949 Cytokinetics shares in Q3 2017, an estimated $205K.
  • Alambic Investment Management first reported a position in Cytokinetics in Q4 2016 and held it in 3 quarters.
  • Alambic Investment Management's Cytokinetics position peaked at $366K in Q1 2017.
  • 132 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2017.

Based on Alambic Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.